Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
About Us
News and Events
My HPRA:
Login
Register
About Us
Our Mission, Vision and Values
What We Regulate and How We Regulate
Our Strategic Plan 2021 – 2025
Contact Us
Our Structure
Patient Forum
Publications & Forms
Standards of Service
Privacy and Data Protection
Information and transparency
Consultations
Quality Management
Recruitment
Report an Issue
Legislation
Extranets
News and Events
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
EMA announces public hearing on quinolone and fluoroquinolone medicines
News Category:
Regulatory news
Date:
10/04/2018
The European Medicines Agency (EMA) has opened registration for its next public hearing which will take place on 13 June 2018 at the EMA’s offices in London. The public hearing will provide patients, healthcare professionals and other stakeholders with the opportunity to share experience with
quinolones and fluoroquinolones
, a class of antibiotics widely prescribed in the EU.
The public hearing is part of a review being carried out by EMA’s safety committee, the Pharmacovigilance Risk Assessment Committee (or PRAC).
Further details, including practical information on the public hearing process, are available from the EMA's website.
« Back
Date Printed: 16/04/2024